MENU

CRMD Stock CorMedix (CRMD, $12.5) price may climb as it broke lower Bollinger Band on Jun 27, 2025

A.I.dvisor
at Tickeron.com
Loading...
CRMD - CorMedix
Bollinger signal
Bullish Trend
Odds of UP Trend
Tickeron
Bollinger signal
Price: $12.5
Daily change: -$2.46 (-16.44%)
Daily volume: 9.9M
Capitalization: $847.8M
Industry: Biotechnology
This price move could be a signal that CRMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. A.I.dvisor backtested 36 similar cases where CRMD's price broke its lower Bollinger Band, and of them led to a successful outcome. Odds of Success:

CRMD in upward trend: price expected to rise as it breaks its lower Bollinger Band on June 27, 2025

CRMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 36 cases where CRMD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRMD advanced for three days, in of 276 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 173 cases where CRMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CRMD moved out of overbought territory on June 24, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on June 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CRMD as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CRMD turned negative on June 26, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRMD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.380) is normal, around the industry mean (16.366). P/E Ratio (50.000) is within average values for comparable stocks, (58.189). CRMD's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (9.346) is also within normal values, averaging (252.247).

View a ticker or compare two or three
CRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of medical devices for cardiovascular and kidney diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
300 Connell Drive
Phone
+1 908 517-9500
Employees
83
Web
https://www.cormedix.com